ClinicalTrials.gov
ClinicalTrials.gov Menu

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00074490
Recruitment Status : Terminated (Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2)
First Posted : December 15, 2003
Results First Posted : December 31, 2018
Last Update Posted : December 31, 2018
Sponsor:
Information provided by (Responsible Party):
Steven Pavletic, M.D., National Institutes of Health Clinical Center (CC)

Brief Summary:

Background:

Patients with cancers of the blood and immune system often benefit from transplants of stem cells from a genetically well-matched sibling. However, severe problems may follow these transplants because of the high-dose chemotherapy and radiation that accompany the procedure. Also, donated immune cells sometimes attack healthy tissues in a reaction called graft-versus-host disease (GVHD), damaging organs such as the liver, intestines and skin. To reduce toxicity of high-dose preparative chemotherapy, this study performs allogeneic transplant after low doses of chemotherapy. In an attempt to improve anti-tumor effects without increasing GVHD, this study uses donor immune cells (T helper 2 (Th2) cells) grown in the laboratory; some patients will receive standard donor immune cells (not grown in laboratory). All patients will receive immune modulating drugs sirolimus and cyclosporine to prevent GVHD.

Objective:

To determine the safety, treatment effects and rate of GVHD in patients receiving transplants that use low-intensity chemotherapy, sirolimus plus cyclosporine, and transplant booster with either Th2 cells or standard immune cells.

Eligibility:

Patients 16 to 75 years of age with acute or chronic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, or myelodysplastic syndrome.

Patients must have a suitable genetically matched sibling donor and adequate kidney, heart and lung function.

Design: The protocol has three treatment groups: cohort 1, Th2 booster at two weeks post-transplant; cohort 2, standard T cell booster at two weeks post-transplant; cohort 3, multiple infusion of Th2 cells.

Condition: Hematologic Neoplasms, Myeloproliferative Disorders

Intervention: Biological; therapeutic allogeneic lymphocytes

Drug: Sirolimus

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Phase: Phase II


Condition or disease Intervention/treatment Phase
Lymphoma Leukemia Myeloproliferative Disorders Multiple Myleoma Myelodysplastic Syndrome Drug: Rituximab Drug: Fludarabine Drug: Etoposide Drug: Doxorubicin Drug: Vincristine Drug: Cyclophosphamide Procedure: Peripheral blood stem cell (PBSC) transplantation Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells Drug: Prednisone Procedure: Allogeneic hematopoietic stem cell transplant (HSCT) Drug: Filgrastim Genetic: T-Rapa cell Donor Lymphocyte Infusion (DLI) Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 442 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
Actual Study Start Date : January 1, 2004
Actual Primary Completion Date : July 20, 2017
Actual Study Completion Date : August 16, 2017


Arm Intervention/treatment
Experimental: Arm IVD cohort 1 (Th2 DLI)
Patients receive low intensity fludarabine phosphate intravenous (IV) and cyclophosphamide IV on days -6 to -3. Patients undergo donor lymphocyte infusion (DLI) with sirolimus generated donor T-helper 2 (Th2) cells on day 14 (single T-Rapa cell DLI in patients with cluster of differentiation 4 (CD4) count between 100 and 200 inclusive)
Drug: Fludarabine
Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Fludara

Drug: Cyclophosphamide
Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Cytoxan

Procedure: Peripheral blood stem cell (PBSC) transplantation
PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Allogeneic Hematopoietic Stem Cell Transplant.

Drug: Filgrastim
Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
Other Name: Neupogen

Genetic: T-Rapa cell Donor Lymphocyte Infusion (DLI)
The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).

Experimental: Arm IVD cohort 2 (conventional DLI)
Patients receive low intensity fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3. Patients undergo DLI with unmanipulated donor T-cells on day 14 (single T- cell DLI in patients with low CD4 count between 100 and 200 inclusive)
Drug: Fludarabine
Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Fludara

Drug: Cyclophosphamide
Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Cytoxan

Procedure: Peripheral blood stem cell (PBSC) transplantation
PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).

Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Allogeneic Hematopoietic Stem Cell Transplant.

Drug: Filgrastim
Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
Other Name: Neupogen

Experimental: Arm IVD cohort 3 (multiple Th2 DLI)
Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14 (multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300)
Drug: Rituximab
Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
Other Name: Rituxan

Drug: Fludarabine
Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Fludara

Drug: Etoposide
Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
Other Name: Toposar

Drug: Doxorubicin
Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
Other Name: Doxil

Drug: Vincristine
Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
Other Name: Leurocristine

Drug: Cyclophosphamide
Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Cytoxan

Procedure: Peripheral blood stem cell (PBSC) transplantation
PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Drug: Prednisone
Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
Other Name: Deltasone

Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Allogeneic Hematopoietic Stem Cell Transplant.

Drug: Filgrastim
Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
Other Name: Neupogen

Genetic: T-Rapa cell Donor Lymphocyte Infusion (DLI)
The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).

Experimental: Arm IVA (12-day expanded Th2 DLI)
Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine by mouth twice a day (PO BID) on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic peripheral blood stem cells (PBSC) on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14.
Drug: Fludarabine
Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Fludara

Drug: Cyclophosphamide
Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Cytoxan

Procedure: Peripheral blood stem cell (PBSC) transplantation
PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).

Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Allogeneic Hematopoietic Stem Cell Transplant.

Drug: Filgrastim
Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
Other Name: Neupogen

Experimental: Arm IVB (6-day expanded Th2 DLI)
Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
Drug: Fludarabine
Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Fludara

Drug: Cyclophosphamide
Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Cytoxan

Procedure: Peripheral blood stem cell (PBSC) transplantation
PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).

Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Allogeneic Hematopoietic Stem Cell Transplant.

Drug: Filgrastim
Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
Other Name: Neupogen

Experimental: Arm IVC (6-day expanded Th2 DLI and High-Dose Sirolimus)
Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
Drug: Fludarabine
Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Fludara

Drug: Cyclophosphamide
Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Other Name: Cytoxan

Procedure: Peripheral blood stem cell (PBSC) transplantation
PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).

Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Allogeneic Hematopoietic Stem Cell Transplant.

Drug: Filgrastim
Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
Other Name: Neupogen




Primary Outcome Measures :
  1. Percentage of Patients to Receive T Cell Infusion [ Time Frame: first 100 days post-transplant ]
    T cells administered by intravenous infusion after patient received transplant.

  2. Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD) [ Time Frame: first 100 days post-transplant ]
    GVHD of the skin, liver and gut were graded on a scale of 1, 2, 3, and 4 (e.g. the grades are not added together) using the National Institutes of Health Consensus Criteria. Grade 1 is minimal GVHD, Grade 2 is moderate GVHD, Grade 3 is severe GVHD and Grade 4 is very severe GVHD. Grade 4 is a worse outcome than Grade 1.


Secondary Outcome Measures :
  1. Detection of of Post-transplantation Cluster of Differentiation 4 (CD4)+ and CD8+ T-cell Production of T Helper 1 -2 (Th1-Th2)-Type Cytokines [ Time Frame: First 100 days post-transplant ]
    Detection of cytokine secretion was done by enzyme-linked immunosorbent assay.

  2. Percentage of Patients With Opportunistic Infection [ Time Frame: First 100 days post-transplant ]
    Participants are susceptible to opportunistic infections such as bacterial, fungal, viral, protozoan infections and more due to immune suppression from chemotherapy drugs used to treat their disease.

  3. Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0) [ Time Frame: Date treatment consent signed to date off study, approximately 5 years ]
    Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   11 Years to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA: PATIENT RECIPIENT

    1. Patients with hematologic malignancies, myelodysplasia, or myeloproliferative disorders, as summarized in the following table. The diagnosis must be histologically confirmed by the Laboratory of Pathology of National Cancer Institute (NCI) or Hackensack (There will be no central pathology review).
    2. Chronic Lymphocytic Leukemia - Disease Status: a) Relapse post-fludarabine, b) Non-Complete Response (CR) after salvage regimen.

      Hodgkin's and Non-Hodgkin's Lymphoma (all types, including Mantle Cell Lymphoma) - Disease Status: a) Primary treatment failure, b) Relapse after autologous stem cell transplant (SCT), c) Non-CR after salvage regimen

      Special Cases of High-Risk Lymphoma, including but not limited to : (1) plasma dendritic cell type, 2) Hepato-splenic T cell type, 3) gamma delta pinniculitic T cell type, 4) Muco-cutaneous natural killer (NK) cell type and 5) stage III-IV nasal NK cell type- Disease Status: a) Primary treatment failure, b) Relapse after autologous, c) Non-CR after salvage regimen, d) In first CR or any later CR

      Chronic Epstein Barr Virus (EBV)-associated lymphoproliferative disease a) At any point after diagnosis, including up-front therapy

      Multiple Myeloma - Disease Status: a) Primary treatment failure, b) Relapse after autologous stem cell transplant (SCT), c) Non-CR after salvage regimen.

      Acute Myelogenous Leukemia - Disease Status: a) CR number 1 and high-risk [excludes t(8;21), t(15;17), or inv(16)], b) CR number 2 or greater).

      Acute Lymphocytic Leukemia - Disease Status: a) CR number 1 plus high-risk [t(9;22) or bcr-abl(+); t(4;11), 1(1;19), t(8;14)], b) In CR number2 or greater.

      Myelodysplastic Syndrome - Disease Status: a) Refractory Anemia with Excess Blasts (RAEB), b) Refractory Anemia with Excess Blasts in Transformation (RAEB-T) (requires marrow and blood blasts less than 10% after induction chemotherapy).

      Myeloproliferative disorders - Disease Status: a) Idiopathic myelofibrosis, b) Polycythemia vera, c) Essential thrombocytosis, d) Chronic myelomonocytic leukemia.

      Chronic Myelogenous Leukemia (CML) - Disease Status: a) Chronic phase CML, refractory to imatinib treatment b) Accelerated phase CML. b) Accelerated phase CML

      Patients with myeloproliferative disorders must be end-stage, which is primarily defined as disease severity refractory to splenectomy.

    3. Patient age of 16 to 75 years.
    4. Consenting first degree relative matched at 6/6 HLA antigens (A, B, and DR).
    5. Patient or legal guardian must be able to give informed consent.
    6. All previous intravenous therapy administered outside of the National Institutes of Health (NIH) Clinical Center must be completed at least 2 weeks prior to study entry, with recovery to less than or equal to non-hematologic grade 2 toxicity of previous therapy.
    7. Eastern Cooperative Oncology Group (ECOG) performance status equal to 0 or 1.
    8. Life expectancy of at least 3 months.
    9. Patients with acute leukemia must have chemotherapy sensitive disease, as defined by at least a 50% reduction in circulating absolute blast count due to the most proximal regimen.
    10. Left ventricular ejection fraction greater than or equal to 45%, preferably by 2-dimension (2-D) echo, or by multi-gated acquisition scan (MUGA). However, patients with left ventricular ejection fraction (LVEF) of between 35% and 44% may also be eligible provided that such patients are cleared by a Cardiology Consultation that must include a cardiac stress test.
    11. Corrected diffusing capacity or transfer of the lung for carbon monoxide (DLCO) greater than 50% of expected value.
    12. Creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than or equal to 50 ml/min.
    13. Serum total bilirubin less than 2.5 mg/dl; serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal 2.5 times upper limit of normal. Values above these levels may be accepted, at the discretion of the principal investigator (PI) or study chairman, if such elevations are thought to be due to liver involvement by malignancy or graft versus host disease (GVHD).
    14. Adequate central venous access potential.
    15. Potential patients referred for the study may not be eligible for the experimental protocol therapy due to reasons such as uncertainty about donor human leukocyte antigen (HLA) typing or need to control malignant disease, infection, or metabolic abnormality such as hypercalcemia on a emergent basis. Should a referred patient present to us in such a scenario, the patient will be referred back to their primary hematologist-oncologist for treatment. However, if referral back to the referring physician is not in the best interest of the patient according to the clinical judgement of the principal investigator (PI), then the patient may receive standard treatment for the malignant disease or complicating conditions (infection, metabolic problems under the current study. In other cases, a patient may have reasonable control of malignancy but does not meet the cluster of differentiation 4 (CD4) cell cut-off of 50 cells per microliter required for cohort 3 therapy; in such cases, standard care chemotherapy regimens may be administered for the specific goal of reducing the CD4 count (that is, immune depleting regimens such as the pentostatin plus cyclophosphamide combination, administered similar to the manner that we have developed on protocol 08-C- 0088). If it becomes apparent that the patient will not be able to proceed to experimental therapy, then he/she must come off study. Recipient-Subjects receiving a standard therapy, and availability of receiving the same treatment elsewhere, outside of a research protocol. Because such standard care therapy is not experimental, it is not necessary to complete the eligibility criteria prior to receiving such standard care; however, prior to initiation of the experimental therapy, the patient must meet each of the eligibility criteria detailed above. Attempts will be made to standardize such pretransplant chemotherapy (by administration of etoposide, prednisolone, oncovin, cyclophosphamide, hydroxydaunorubicin, fludarabine, rituximab (EPOCH-FR) chemotherapy, which is detailed later in this protocol); however, other regimens using approved agents will be allowed if such regimens are thought to be in the best interest of the patient.

INCLUSION CRITERIA: DONOR

  1. First-degree relative with genotypic identity at 6/6 HLA loci (HLA- A, B, and DR).
  2. Age 11 to 90 years and able to give consent or assent. For donors < 18 years old, the legal guardian must be able to provide informed consent.
  3. Adequate venous access for peripheral apheresis, or consent to use a temporary central venous catheter for apheresis.
  4. Donors must be human immunodeficiency virus (HIV) negative.
  5. Donors with a history of hepatitis B or hepatitis C infection may be eligible. However, eligibility determination of such patients will require a hepatology consultation. The risk/benefit of the transplant and the possibility of transmitting hepatitis will be discussed with the patient and eligibility will then be determined by the principal investigator and lead associate investigator (LAI).
  6. Lactating donors must substitute formula feeding for her infant during period of filgrastim administration (to prevent any filgrastim effect on infant).

EXCLUSION CRITERIA: PATIENT

  1. Active infection that is not responding to antimicrobial therapy.
  2. Active central nervous system (CNS) involvement by malignancy.
  3. HIV infection (treatment may result in progression of HIV and other viral infections).
  4. Chronic active hepatitis B. Patient may be hepatitis B core antibody positive. For patients with concomitant positive hepatitis B surface antigen, patient will require a hepatology consultation. The risk/benefit profile of transplant and hepatitis B will be discussed with the patient and eligibility determined by the principal investigator and Lead Associate Investigator.
  5. Hepatitis C infection. Patient may have hepatitis C infection. However, each patient will require a hepatology consultation. The risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and Lead Associate Investigator.
  6. Pregnant or lactating. Patients of childbearing potential must use an effective method of contraception. The effects of the chemotherapy, the subsequent transplant and the medications used after the transplant are highly likely to be harmful to a fetus. The effects upon breast milk are also unknown and may be harmful to the infant.
  7. History of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consent.

EXCLUSION CRITERIA: DONOR

  1. History of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consent.
  2. History of hypertension that is not controlled by medication, stroke, autoimmune disease, or severe heart disease (donors with symptomatic angina will be excluded). Donors with a history of coronary artery bypass grafting or angioplasty who are symptom free will receive a cardiology evaluation and be considered on a case-by-case basis.
  3. History of prior malignancy. However, cancer survivors who have undergone potentially curative therapy may be considered for stem cell donation on a case-by-case basis. In addition, donors with localized cancer such as prostate cancer that are on a watch-and-wait management due to the low-risk of disease progression may also be considered for stem cell donation on a case-by-case basis. The risk/benefit of the transplant and the possibility of transmitting viable tumor cells at the time of transplantation will be discussed with the patient.
  4. Donors must not be pregnant (unknown effect of filgrastim on fetus). Donors of childbearing potential must use an effective method of contraception.
  5. Anemia (Hemoglobin (Hb) less than 11 gm/dl) or thrombocytopenia (platelets less than 100,000 per microliter). However, potential donors with Hb levels less than 11 gm/dl that is due to iron deficiency will be eligible as long as the donor is initiated on iron replacement therapy and the case is individually approved by National Institutes of Health (NIH) or Hackensack Blood Bank.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00074490


Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Steven Z Pavletic, M.D. National Cancer Institute (NCI)
  Study Documents (Full-Text)

Documents provided by Steven Pavletic, M.D., National Institutes of Health Clinical Center (CC):

Additional Information:
Publications of Results:
Other Publications:
Responsible Party: Steven Pavletic, M.D., Principal Investigator, National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00074490     History of Changes
Obsolete Identifiers: NCT00077480
Other Study ID Numbers: 040055
04-C-0055
First Posted: December 15, 2003    Key Record Dates
Results First Posted: December 31, 2018
Last Update Posted: December 31, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Steven Pavletic, M.D., National Institutes of Health Clinical Center (CC):
Leukemia
Lymphoma
Multiple Myeloma
Bone Marrow Transplantation
Immune Therapy

Additional relevant MeSH terms:
Lymphoma
Syndrome
Leukemia
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Cyclophosphamide
Fludarabine phosphate
Sirolimus
Everolimus
Rituximab
Liposomal doxorubicin
Fludarabine
Etoposide phosphate
Doxorubicin
Prednisone
Etoposide
Vincristine
Lenograstim